

Journal Club Articles

1. **Twenty-five year follow up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: Randomized Screening Trial**
Miller et.al; BMJ 2014
2. **Effect of ACEI and ARB on All-Cause Mortality, Cardiovascular Death and Cardiovascular Events in Patients with Diabetes Mellitus. A Meta-Analysis**
Cheng et.al; JAMA 2014
3. **Age-Adjusted D-Dimer Cutoff Levels to Rule out Pulmonary Embolism. The ADJUST-PE Study**
Righini, Van Es et. Al.; JAMA 2014
4. **Changes in Mortality after Massachusetts Health Care Reform**
Sommers, Long et. Al; Annals of Internal Medicine; May 6th, 2014
5. **Health Care-Associated Infection after Red Blood Cell Transfusion. A Systematic Review and Meta-Analysis**
Rohde et.al; JAMA 2014
6. **Aspirin in Patients Undergoing Noncardiac Surgery**
Devereaux et al; NEJM April 2014
7. **Albumin Replacement in Patients with Severe Sepsis or Septic Shock**
Caironi et al; NEJM April 2014
8. **A Randomized Trial of Protocol-Based Care for Early Septic Shock**
The ProCESS Investigators; NEJM March 18th, 2014
9. **High versus Low Blood-Pressure Target in Patients with Septic Shock**
Asfar et.al; NEJM March 18th, 2014
10. **Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock**
Rivers et.al; NEJM Nov 8th, 2001
11. **Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome.**
Kazi MD, et. Al. Annals of Internal Medicine, Feb 2014

12. **Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation (The CURE Trial).**
NEJM 2001
13. **Long Term Mortality after Screening for Colorectal Cancer.**
Shaukat A, Mongin SJ, Geisser MS, et al. NEJM 2013
14. **Upper Airway Stimulation for Obstructive Sleep Apnea.**
Strollo, Soose, Maurer et al. NEJM 2014
15. **Bariatric Surgery vs. non-surgical treatment for obesity.**
Gloy, Bhatt, et al. BMJ 2013
16. **Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial**
Bouadma et al; Lancet, 2010
17. **Body-Mass Index and Mortality among Adults with Incident Type 2 Diabetes**
Tobias et al; NEJM Jan 16th, 2014
18. **2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)**
JAMA December 2013
19. **Heart Association Task Force on Practice Guidelines Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic**
Circulation 2013
20. **Worsening Trends in the Management and Treatment of Back Pain**
JAMA 2013
21. **Effects of Vitamin D supplements on bone mineral density: A systematic review and meta-analysis**
22. **Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy (NEJM).**
November 2013
23. **Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy.**
REENAL Study (NEJM) 2001

24. **Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy (NEJM).**
November 2013
25. **Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy.**
RENAL Study (NEJM) 2001
26. **Aggressive Fluid and Sodium Restriction in Acute Decompensated Heart Failure**
JAMA, June 2013
27. **Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)**
The Lancet, June 1999
28. **Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. The REDUCE Randomized Clinical Trial.**
JAMA, May 2013
29. **Effect of Home Blood Pressure Telemonitoring and Pharmacist Management on Blood Pressure Control: A Cluster Randomized Clinical Trial**
Margolis et. al; JAMA July 3, 2013
30. **Therapies for Active Rheumatoid Arthritis after Methotrexate Failure**
O'Dell et al; NEJM July 25, 2013
31. **Diagnostic Blood Loss From Phlebotomy and Hospital-Acquired Anemia During Acute Myocardial Infarction**
Salisbury et al; Arch Intern Med; October 10, 2011
32. **“Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women”**
BMJ
33. **“Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women” (results from the Women’s Health Initiative)**
JAMA
34. **“Associations Between Reduced Hospital Length of Stay and 30 Day Readmission Rate & Mortality”**
Annals of Internal Medicine

35. **Dietary and Supplemental Calcium Intake and Cardiovascular Disease Mortality**
The National Institutes of Health
36. **Blood Pressure and Mortality in U.S. Veterans with Chronic Kidney Disease**
Annals of Internal Medicine
37. **Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes**
The New England Journal of Medicine
38. **Association Between Chlorthalidone Treatment of Systolic Hypertension and Long-term Survival**
JAMA, December 21, 2011
39. **Screening for Lung Cancer with Low-Dose Computed Tomography: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation**
Annals of Internal Medicine
40. **Twenty-five year follow up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: Randomized Screening Trial**
Miller et.al; BMJ 2014
41. **Effect of ACEI and ARB on All-Cause Mortality, Cardiovascular Death and Cardiovascular Events in Patients with Diabetes Mellitus. A Meta-Analysis**
Cheng et.al; JAMA 2014
42. **Twenty-five year follow up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: Randomized Screening Trial**
Miller et.al; BMJ 2014
43. **Effect of ACEI and ARB on All-Cause Mortality, Cardiovascular Death and Cardiovascular Events in Patients with Diabetes Mellitus. A Meta-Analysis**
Cheng et.al; JAMA 2014
44. **Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD**
Criner et. al
NEJM June 14, 2014
45. **Atrial Fibrillation in Patients with Cryptogenic Stroke**
Gladstone et. al

NEJM June 26, 2014

46. **Once weekly Dalbavancin versus conventional therapy for skin infection**
Boucher, et. al
NEJM June 5th, 2014
47. **Pregnancy Incidence and Outcomes Among Women Receiving Pre-exposure Prophylaxis for HIV Prevention: A Randomized Clinical Trial**
Nelly R. Mugo, MBChB, MPH^{1,2,3}; et. al

<http://jama.jamanetwork.com/article.aspx?articleid=1889140&resultClick=3>
48. **Telecare Collaborative Management of Chronic Pain in Primary Care: A Randomized Clinical Trial**
Kurt Kroenke, MD^{1,2,3}; Erin E. Krebs, MD^{4,5}; Jingwei Wu, MS⁶; Zhangsheng Yu, PhD⁶; Neale R. Chumbler, PhD⁷; Matthew J. Bair, MD^{1,2,3}

<http://jama.jamanetwork.com/article.aspx?articleid=1887761&resultClick=3>
49. **Efficacy of Varenicline Combined With Nicotine Replacement Therapy vs Varenicline Alone for Smoking Cessation: A Randomized Clinical Trial**
Coenraad F. N. Koegelenberg, MD, PhD¹; et.al

<http://jama.jamanetwork.com/article.aspx?articleid=1886188>
50. **Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer**
Jennifer S. Temel, M.D., Joseph A. Greer, Ph.D., et.al
N Engl J Med 2010; 363:733-742 August 19, 2010 DOI: 10.1056/NEJMoa1000678
<http://www.nejm.org/doi/full/10.1056/NEJMoa1000678>
51. **Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY Trial)**

Stuart J. Connolly, M.D., Michael D. Ezekowitz, M.B., Ch.B., et.al and the RE-LY Steering Committee and Investigators

N Engl J Med 2009; 361:1139-1151 [September 17, 2009](http://www.nejm.org/doi/full/10.1056/NEJMoa0901056)
52. **Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results from Two Multinational, Randomized, Controlled Trials**

Stuart Johnson, Thomas Louie, et. al for the Polymer Alternative for CDI Treatment (PACT) investigators

Clinical Infectious Diseases; July 2014

53. **The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy**
Michiel Coppens, John W. Eikelboom et. Al
European Heart Journal, September 2012
54. **The Risk of Melanoma in Airline Pilots and Cabin Crew**
Martina Sanlorenzo, MD et.al
JAMA Dermatol. Published online September 03, 2014
55. **Cardiovascular Risk and Events in 17 Low, Middle and High-Income Countries**
S. Yusuf et.al
NEJM, August 28, 2014
56. **Angiotensin-Nepriylsin Inhibition versus Enalapril in Heart Failure**
J.J. McMurray et. al
NEJM, September 11th, 2014
57. **The Risk of Melanoma in Airline Pilots and Cabin Crew**

Martina Sanlorenzo, MD et. al
JAMA Dermatol. Published online September 3, 214
58. **Cardiovascular Risk and Events in 17 Low, Middle and High-Income Countries**
S. Yusuf et. al
NEJM, August 28, 2014
59. **Angiotensin-Nepriylsin Inhibition versus Enalapril in Heart Failure**
J.J. McMurray et. al
NEJM, September 11, 2014
60. **A Controlled Trial of Renal Denervation for Resistant Hypertension**
Deepak L. Bhatt, M.D., M.P.H., David E. Kandzari, M.D et.al for the SYMPPLICITY HTN-3 Investigators

NEJM, March 29th, 2014

61. **Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes who do not have Adequate Glycemic Control With Metformin Plus Sulfonylurea**
G. Schernthaner, J. Gross et.al

Diabetes Care, April 5, 2013
62. **Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes**
Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., et.al for the STAMPEDE Investigators

NEJM, March 31, 2014
63. **Multitarget Stool DNA Testing for Colorectal-Cancer Screening**
Thomas F. Imperiale, et. Al
NEJM April 3rd, 2014
64. **A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis**

B. Joseph Elmunzer, et. al
NEJM April 12, 2012
65. **Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis**
Kris V. Kowdley, et. al
NEJM May 15, 2014
66. **Goal-Directed Resuscitation for Patients with Early Septic Shock**
The ARISE Investigators and the ANZICS Clinical Trials Group*
October 1st, 2014
67. **Fractional Flow Reserve–Guided PCI for Stable Coronary Artery Disease**
Bernard De Bruyne, M.D., Ph.D. et.al
NEJM September 2014
68. **Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients**
The HPS2-THRIVE Collaborative Group*
NEJM July 2014
69. **Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 years or Older with Atherosclerotic Risk Factors**
Y. Ikeda et. al, JAMA, November 17, 2014
<http://jama.jamanetwork.com/article.aspx?articleid=1936801>

70. **Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial**
J. Cuzick et.al, Lancet, December 2014
[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(14\)71171-4/abstract](http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71171-4/abstract)
71. **A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women**
P. Ridker et.al, NEJM, March 200
<http://www.nejm.org/doi/full/10.1056/NEJMoa050613>
72. **The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop**
Roger Chou, MD et. Al
Annals of Internal Medicine, Feb 17th, 2015
73. **Cost-Effectiveness of Hypertension Therapy According to 2014 Guidelines**
Andrew E. Moran, M.D., M.P.H., Michelle C. Odden, Ph.D., et.al
N Engl J Med January 29, 2015
74. **Perioperative Atrial Fibrillation and the Long-term Risk of Ischemic Stroke**
Gino Gialdini, MD1; Katherine Nearing, MD2; et.al
JAMA, August 13th, 2015
75. **Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection**
Emily G. McDonald, MD et.al

JAMA, March 2, 2015
76. **Association of NSAID Use With Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction**
Anne-Marie Schjerning Olsen, MD et.al
JAMA Feb 24, 2015
77. **Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage A Meta-analysis**
Saurav Chatterjee, MD et.al
JAMA, June 18, 2014
78. **Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults**

- Douwe F. Postma, M.D et. Al
NEJM, April 2nd, 2015
79. **Trial of Early, Goal-Directed Resuscitation for Septic Shock**
Paul R. Mouncey, M.Sc., Tiffany M. Osborn, M.D et.al
NEJM, April 2nd, 2015
80. **Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease**
Pamela S. Douglas, M.D., et.al
NEJM, April 2nd, 2015
81. **Prednisolone or Pentoxifylline for Alcoholic Hepatitis**
Mark R. Thursz, M.D et.al
NEJM, April 23rd, 2015
82. **Association of Early Imaging for Back Pain with Clinical Outcomes in Older Adults**
Jeffrey Jarvik, MD et.al
JAMA March 17, 2015
83. **Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials**
Gustavo C Machado, PhD, et.al
BMJ, March 2015
84. **Clindamycin versus Trimethoprim–Sulfamethoxazole for Uncomplicated Skin Infections**
Loren G. Miller, M.D., M.P.H., et.al
NEJM March 19, 2015
85. **Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.**
Walters JA et.al
Cochrane Database Syst Rev. 2014.
86. **Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: The SECURITY randomized clinical trial.**
Colombo A, Chieffo A, Frasher A, et al.
J Am Coll Cardiol. 2014

87. **Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial.**

Mismetti P et. al

JAMA. 2015 Apr 28;313(16):1627-35.

88. **Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures**

Nathan P. Clark, PharmD^{1,2}; Daniel M. Witt, PharmD^{1,3}; et.al

JAMA Intern Med. Published online May 26, 2015

89. **Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial**

Louis Bernard, Aurélien Dinh, Idir Ghout, David Simo, Valerie Zeller, et.al on behalf of the Duration of Treatment for Spondylodiscitis (DTS) study group*

Lancet, Vol 385 March 7, 2015

90. **A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management**

Xavier Pi-Sunyer, M.D., Arne Astrup, M.D., D.M.Sc., Ken Fujioka, M.D., Frank Greenway, M.D., et.al for the SCALE Obesity and Prediabetes NN8022-1839 Study Group*

NEJM, July 2, 2015

91. **Effects of intensive blood-pressure control in type 2 diabetes mellitus**

Cushman WC, Evans GW, Byington RP, et al.

N Engl J Med. 2010;362(17):1575-1585.

92. **Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial**

Ruggenti P, Perna A, Loriga G, et al.

Lancet. 2005;365(9463):939-946

93. **Telmisartan, ramipril, or both in patients at high risk for vascular events.**

Yusuf S, Teo KK, Pogue J, et al.

- N Engl J Med. 2008;358(15):1547-1559.
94. **Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer**
Jennifer S. Temel, M.D., Joseph A. Greer, Ph.D., et.al
N Engl J Med August 19, 2010; 363:733-742
 95. **Patients’ Expectations about Effects of Chemotherapy for Advanced Cancer**
Jane C. Weeks, M.D, et. al
N Engl J Med 2012;367:1616-25.
 96. **Chemotherapy Use, Performance Status, and Quality of Life at the End of Life**
Holly G. Prigerson, PhD et. Al
JAMA Oncol. July 23, 2015.
 97. **Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial**
Francis Couturaud, MD, PhD; Olivier Sanchez, MD, PhD et.al
JAMA July 7 2015
 98. **Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection**
The INSIGHT START Study Group
NEJM August 27, 2015
 99. **Screening for Occult Cancer in Unprovoked Venous Thromboembolism**
Marc Carrier, M.D., Alejandro Lazo-Langner, M.D., et.al
NEJM August 20, 2015
 100. **Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation**
James D. Douketis, M.D., Alex C. Spyropoulos MD, et.al
NEJM August 27, 2015
 101. **Terlipressin Plus Albumin Versus Midodrine and Octreotide Plus Albumin in the Treatment of Hepatorenal Syndrome: A Randomized Trial**
Marta Cavallin, et. Al
Hepatology, August 2015
 102. **Intravascular Complications of Central Venous Catheterization by Insertion Site**
Jean-Jacques Parienti, et. al
NEJM, September 25, 2015

103. **Effect Of Intravenous Albumin On Renal Impairment and Mortality in Patients With Cirrhosis And Spontaneous Bacterial Peritonitis**
Pau Sort, et.al
NEJM, 1999
104. **Calcium intake and risk of fracture: systematic review.**
Bolland MJ, Leung W, Tai V, et al.
BMJ. 2015 Sep 29
105. **Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes**
Zinman B, Wanner C, Lachin JM, et al.
N Engl J Med. 2015 Sep 17
106. **Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2)**
Williams B, MacDonald TM, Morant S, et al.
Lancet. 2015 Sep 18
107. **Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain**
Benjamin W. Friedman, MD et.al
JAMA October 20, 2015
108. **Beta-Blocker-Associated Risks in Patients With Uncomplicated Hypertension Undergoing Noncardiac Surgery.**
Jorgensen ME, Hlatky MA, Kober L, et al.
JAMA, October 5, 2015
109. **A Randomized Trial of Intensive versus Standard Blood-Pressure Control**
The SPRINT Research Group
NEJM, November 26, 2015
110. **Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease**
Steven P. Sedlis, M.D. et.al
NEJM, November 12, 2015
111. **Stroke and recurrent hemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study.**
Staerk L, Lip GY, Olesen JB, et al.
BMJ Nov 2015

112. **Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database.**
van den Ham HA, Klungel OH, Singer DE, et al.
J Am Coll Cardiol. 2015 Oct
113. **A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation**
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
Investigators
N Engl J Med 2002
114. **Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)**
Umpierrez GE¹, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, Puig A, Mejia R
Diabetes Care. 2007 Sep;30(9):2181-6. Epub 2007 May 18.
115. **Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)**
UK Prospective Diabetes Study (UKPDS) Group.
Lancet. 1998 Sep 12
116. **Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes**
Rodney A. Hayward, M.D., Peter D. Reaven, M.D., et.al for the VADT Investigators
NEJM June 4, 2015
117. **Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection**
The INSIGHT START Study Group
NEJM August 27, 2015
118. **Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention A Randomized Trial**
Lindsey R. Baden, MD; Etienne Karita, MD et.al
Annals of Internal Medicine Feb 2016

119. **Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis**
David R. Boulware, M.D., M.P.H., et.al for COAT Trial Team
NEJM June 26 2014

120. **Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection**
The INSIGHT START Study Group
NEJM August 27, 2015

121. **Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention A Randomized Trial**
Lindsey R. Baden, MD; Etienne Karita, MD et.al
Annals of Internal Medicine Feb 2016

122. **Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis**
David R. Boulware, M.D., M.P.H., et.al for COAT Trial Team
NEJM June 26 2014

123. **Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection**
The INSIGHT START Study Group
NEJM August 27, 2015

124. **Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention A Randomized Trial**
Lindsey R. Baden, MD; Etienne Karita, MD et.al
Annals of Internal Medicine Feb 2016

125. **Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis**
David R. Boulware, M.D., M.P.H., et.al for COAT Trial Team
NEJM June 26 2014

126. **Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score**
MAJ David C. Hostler et.al
Chest 2015

127. **Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess**
David A. Talan et.al
NEJM March 3, 2016

128. **HbA1c over-testing and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study**
Rozalina G McCoy et.al
BMJ 2015

129. **Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score**
MAJ David C. Hostler et.al
Chest 2015

130. **Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess**
David A. Talan et.al
NEJM March 3, 2016

131. **HbA1c over-testing and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study**
Rozalina G McCoy et.al
BMJ 2015

132. **Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score**
MAJ David C. Hostler et.al
Chest 2015

133. **Trimethoprim–Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess**
David A. Talan et.al
NEJM March 3, 2016

134. **HbA1c over-testing and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study**
Rozalina G McCoy et.al
BMJ 2015

135. **Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation (SPINAF)**
Michael D. Ezekowitz, M.D., Ph.D., Samuel L. Bridgers, M.D. et.al
NEJM 1992

- 136. Rivaroxaban versus Warfarin in Non-Valvular Atrial Fibrillation (ROCKET AF)**
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D. et.al
NEJM Sept 8, 2011
- 137. Warfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation (SPINAF)**
Michael D. Ezekowitz, M.D., Ph.D., Samuel L. Bridgers, M.D. et.al
NEJM 1992
- 138. Rivaroxaban versus Warfarin in Non-Valvular Atrial Fibrillation (ROCKET AF)**
Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D. et.al
NEJM Sept 8, 2011
- 139. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy**
Eric J. Velazquez, M.D., Kerry L. Lee, Ph.D., et.al for the STICHES Investigators*
NEJM April 21, 2016
- 140. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease**
Yusuf S, Bosch J, Dagenais G, et al. for the HOPE-3 Investigators
NEJM April 2, 2016
- 141. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes**
Christopher P. Cannon, M.D., Michael A. Blazing, M.D., et.al for the IMPROVE-IT Investigators
NEJM June 18, 2015
- 142. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy**
Eric J. Velazquez, M.D., Kerry L. Lee, Ph.D., et.al for the STICHES Investigators*
NEJM April 21, 2016
- 143. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease**

Yusuf S, Bosch J, Dagenais G, et al. for the HOPE-3 Investigators
NEJM April 2, 2016

144. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Christopher P. Cannon, M.D., Michael A. Blazing, M.D., et.al for the IMPROVE-IT
Investigators
NEJM June 18, 2015

145. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy

Eric J. Velazquez, M.D., Kerry L. Lee, Ph.D., et.al for the STICHES Investigators*
NEJM April 21, 2016

146. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Yusuf S, Bosch J, Dagenais G, et al. for the HOPE-3 Investigators
NEJM April 2, 2016

147. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Christopher P. Cannon, M.D., Michael A. Blazing, M.D., et.al for the IMPROVE-IT
Investigators
NEJM June 18, 2015

148. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCPI; Clifford S. Deutschman, MD, MS et. Al
JAMA Feb 23 2016

149. Nutritional Support and Outcomes in Malnourished Medical Inpatients: A Systematic Review and Meta-analysis

Bally MR1, Blaser Yildirim PZ2, et. Al
JAMA Jan 2016

150. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Eva M. Lonn, M.D., Jackie Bosch, Ph.D et.al
NEJM April 2016

151. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients

Martin B. Leon, M.D., Craig R. Smith
NEJM April 2016

152. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Mervyn Singer, MD, FRCP¹; Clifford S. Deutschman, MD, MS et. Al
JAMA Feb 23 2016

153. Nutritional Support and Outcomes in Malnourished Medical Inpatients: A Systematic Review and Meta-analysis.

Bally MR1, Blaser Yildirim PZ2, et. Al
JAMA Jan 2016

154. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease

Eva M. Lonn, M.D., Jackie Bosch, Ph.D et.al
NEJM April 2016

155. *Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients*

Martin B. Leon, M.D., Craig R. Smith
NEJM April 2016

156. *Invasive versus conservative strategy in patients aged 80 years or older with NSTEMI or unstable angina pectoris (After Eighty study)*

Nicolai Tegn, Michael Abdelnoor, et.al
Jan 12, 2016 (Lancet)

157. *Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack*

S. Claiborne Johnston, M.D., Ph.D., Pierre Amarenco, M.D., et. Al for the
SOCRATES Steering Committee and Investigators
May 10, 2016 (NEJM)

158. ***Invasive versus conservative strategy in patients aged 80 years or older
with NSTEMI or unstable angina pectoris (After Eighty study)***

Nicolai Tegn, Michael Abdelnoor, et.al
Jan 12, 2016 (Lancet)

159. ***Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic
Attack***

S. Claiborne Johnston, M.D., Ph.D., Pierre Amarenco, M.D., et. Al for the
SOCRATES Steering Committee and Investigators
May 10, 2016 (NEJM)